Definition And Epidemiology
- Obliterative cholangiopathy affecting extrahepatic and intrahepatic bile ducts.
- Presents in first few weeks of life with jaundice, pale stools, dark urine.
- Most common cause of pediatric liver transplantation worldwide.
- Incidence varies globally; 1:15,000-20,000 live births in Europe and North America, 1:5,000-10,000 in Asia.
- Female predominance observed specifically in syndromic forms.
Etiology And Classification
Pathogenesis
- Multifactorial origin resulting in final common phenotype of biliary inflammation, luminal obliteration, and fibrosis.
- Postulated mechanisms include congenital failure of bile duct development and perinatal viral or immune-mediated duct destruction.
Clinical Variants
| Variant | Characteristics |
|---|---|
| Isolated Biliary Atresia | Accounts for 80-90% of cases. Typical variant. Elevated direct bilirubin at 24-48 hours implies prenatal onset. |
| Syndromic Biliary Atresia | Accounts for ~15% of cases. Associated with biliary atresia splenic malformation (BASM) syndrome. Features include polysplenia/asplenia, situs inversus, absent inferior vena cava, preduodenal portal vein, cardiac anomalies. |
| Cystic Biliary Atresia | Accounts for ~5% of cases. Obvious cyst within obliterated biliary tree. Detectable on antenatal ultrasound. |
| CMV IgM-Positive Biliary Atresia | Accounts for ~10% of cases. Non-Caucasian predominance, older age at diagnosis, higher aspartate aminotransferase, larger spleens, prominent CD4+ Th1+ T-cell infiltrate. Associated with poorer surgical outcome. |
Anatomical Types (Kasai Types)
- Type 1: Atresia of distal bile duct with patent proximal extrahepatic bile duct.
- Type 2: Atresia of common hepatic duct.
- Type 3: Nonpatency of entire extrahepatic biliary system and intrahepatic ducts at hilum. Comprises >95% of cases.
Clinical Presentation
- Healthy-appearing term infant at birth.
- Conjugated jaundice persisting beyond 14 days of age.
- Acholic (pale/white) stools, dark urine.
- Vitamin K-dependent coagulopathy presenting as umbilical stump bleeding or catastrophic intracranial hemorrhage.
- Failure to thrive, fat malabsorption, fat-soluble vitamin deficiencies (A, D, E, K).
- Hepatomegaly; progression to early fibrosis and cirrhosis (ascites, splenomegaly) typically manifesting beyond 100 days of life.
Differential Diagnosis
| Category | Specific Conditions |
|---|---|
| Medical | Neonatal hepatitis, alpha-1 antitrypsin deficiency, Alagille syndrome (paucity of interlobular bile ducts), progressive familial intrahepatic cholestasis (PFIC), congenital TORCH/CMV infections, galactosemia. |
| Surgical | Choledochal malformation, inspissated bile syndrome, spontaneous bile duct perforation. |
Diagnostic Evaluation
Laboratory Investigations
- Biochemistry: Conjugated hyperbilirubinemia (>1 mg/dL if total <5 mg/dL, or >20% if total >5 mg/dL), mildly raised transaminases, significantly elevated gamma-glutamyl transpeptidase (>200 IU/L), normal serum albumin.
- Serum Matrix Metalloproteinase-7 (MMP-7): Highly sensitive and specific biomarker reflecting liver fibrosis severity.
Imaging And Histology
| Modality | Diagnostic Findings |
|---|---|
| Abdominal Ultrasonography | Excludes other surgical causes. Identifies atrophic/non-emptying gallbladder, non-visualized common bile duct. "Triangular cord sign" (fibrous tissue >3 mm anterior to portal vein bifurcation) highly suggestive. Absence of intrahepatic duct dilatation. |
| Hepatobiliary Scintigraphy (HIDA) | Normal hepatic uptake with failure of biliary excretion into bowel at 24 hours. High negative predictive value; visible intestinal excretion effectively rules out biliary atresia. |
| Percutaneous Liver Biopsy | Diagnostic accuracy 90-95%. Demonstrates bile duct proliferation, bile plugs, portal stromal edema, absence of sinusoidal fibrosis. |
| Intraoperative Cholangiogram | Gold standard for evaluating biliary patency. Confirms diagnosis definitively prior to resection. |
Management Protocol
Surgical Intervention
- Kasai Portoenterostomy (KPE): Radical excision of extrahepatic biliary remnants. Anastomosis of denuded portal plate to a 40-50 cm retrocolic Roux-en-Y jejunal loop.
- Optimal Timing: Performance before 60 days of age maximizes restoration of bile flow and long-term native liver survival.
Postoperative And Adjuvant Therapy
- Nutritional Support: Medium-chain triglyceride-based formula to maximize caloric intake and lipid absorption. Rigorous supplementation of fat-soluble vitamins (A, D, E, K).
- Corticosteroids: High-dose systemic steroids utilized to improve jaundice clearance and reduce biochemical markers of liver injury.
- Ursodeoxycholic Acid (UDCA): Administered to improve biochemical liver function and promote choleresis in patients demonstrating restored bile flow.
- Antimicrobial Prophylaxis: Intravenous broad-spectrum antibiotics (e.g., piperacillin-tazobactam, gentamicin) utilized to treat and prevent ascending cholangitis.
Liver Transplantation
- Indicated for failed KPE (persistent uncorrectable jaundice), decompensated cirrhosis, intractable portal hypertension, or severe growth failure.
Complications And Prognosis
Major Complications
- Ascending Cholangitis: Occurs in 40-50% post-KPE. Features fever, acholic stools, rising bilirubin/transaminases. Requires prompt intravenous antibiotics.
- Portal Hypertension: Results from progressive hepatic fibrosis. Manifests as esophageal/gastric varices, hypersplenism, ascites. Managed via endoscopic surveillance, variceal banding, or portosystemic shunts.
Prognostic Outcomes
- KPE achieves jaundice clearance in 50-60% of infants at experienced, high-volume centers.
- Native liver survival is approximately 50% at 5 years post-KPE.
- Overall survival reaches 93% with integrated Kasai portoenterostomy and liver transplantation programs.